{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:36:33Z","timestamp":1790645793648,"version":"4.1.0"},"reference-count":16,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["1R43AR073036-01"],"award-info":[{"award-number":["1R43AR073036-01"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Acne vulgaris, caused by the Gram-positive bacterium Cutibacterium acnes, is a prevalent dermatologic condition with substantial cutaneous and psychological morbidity. Mild acne is treated with topical antibiotics with more severe inflammatory forms requiring the prolonged use of oral antibiotics, resulting in antimicrobial resistance development. Innovative treatment alternatives, providing complete microbicidal eradication with minimal safety issues and limited susceptibility to microbial resistance, are fervently sought. Designed antimicrobial peptides (dAMPs) are engineered analogs of naturally occurring AMPs that possess a reduced likelihood of developing bacterial resistance. Seven novel dAMP sequences were screened for in vitro bactericidal effectiveness against antibiotic resistant C. acnes clinical isolates. Five peptides (RP444, RP551, RP554, RP556, and RP557) exhibited potent in vitro antibacterial activity. The Therapeutic Index, a measure of specificity for killing multidrug resistant C. acnes over mammalian cells, was determined using bioluminescent human keratinocytes. The Therapeutic Index was highest for the disulfide dAMP, RP556, with a value of 130. The lead dAMP candidate RP556, was further evaluated in a multidrug-resistant C. acnes intradermal murine infection model. A topical application of 5 mg\/mL RP556 (0.5%) eliminated infection. If these preclinical results are translated clinically, dAMPs may become a viable topical monotherapy for the treatment of recalcitrant acne infections.<\/jats:p>","DOI":"10.3390\/antibiotics9010023","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T04:05:51Z","timestamp":1578888351000},"page":"23","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Designed Antimicrobial Peptides for Topical Treatment of Antibiotic Resistant Acne Vulgaris"],"prefix":"10.3390","volume":"9","author":[{"given":"Kathryn W.","family":"Woodburn","sequence":"first","affiliation":[{"name":"Riptide Bioscience, Inc., 941 Railroad Avenue, Vallejo, CA 94952, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Jaynes","sequence":"additional","affiliation":[{"name":"Integrative Biosciences, College of Agriculture, Environment and Nutritional Sciences, Tuskegee University, Tuskegee, AL 36088, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Edward","family":"Clemens","sequence":"additional","affiliation":[{"name":"Riptide Bioscience, Inc., 941 Railroad Avenue, Vallejo, CA 94952, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1473-3099(15)00527-7","article-title":"Systematic review of antibiotic resistance in acne: An increasing topical and oral threat","volume":"16","author":"Walsh","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.det.2008.07.001","article-title":"A current review of topical benzoyl peroxide: New perspectives on formulation and utilization","volume":"27","author":"Tanghetti","year":"2009","journal-title":"Dermatol. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1468-3083.2006.01671.x","article-title":"A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris","volume":"20","author":"Layton","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1517\/14728210903251690","article-title":"Emerging drugs for acne","volume":"14","author":"James","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/000155502320323216","article-title":"Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle","volume":"82","author":"Mills","year":"2002","journal-title":"Acta Derm. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"Infectious Diseases Society of America (2008) The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1167\/iovs.17-22243","article-title":"Designed host defense peptides for the treatment of bacterial keratitis","volume":"58","author":"Clemens","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.3389\/fmicb.2019.01688","article-title":"Evaluation of the antimicrobial peptide, RP557, for the broad-spectrum treatment of wound pathogens and biofilm","volume":"10","author":"Woodburn","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e02690-18","DOI":"10.1128\/AAC.02690-18","article-title":"Designed antimicrobial peptides for recurrent vulvovaginal candidiasis treatment","volume":"63","author":"Woodburn","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/02713680590968637","article-title":"A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs","volume":"30","author":"Gordon","year":"2005","journal-title":"Curr. Eye Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/AAC.01923-12","article-title":"Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by gram-negative pathogens","volume":"57","author":"Berthold","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1039\/c2sm25402f","article-title":"Assembley and stability of \u03b1-helical membrane proteins","volume":"8","author":"Heyden","year":"2012","journal-title":"Soft Matter"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"McDowell, A., Barnard, E., Nagy, I., Gao, A., Tomida, S., Li, H., Eady, A., Cove, J., Nord, C.E., and Patrick, S. (2012). An expanded multilocus sequence typing scheme for Propionibacterium acnes: Investigation of \u2018pathogenic\u2019, \u2018commensal\u2019 and antibiotic resistant strains. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041480"},{"key":"ref_15","first-page":"243","article-title":"The use of antimicrobial peptides in ophthalmology: An experimental study in corneal preservation and the management of bacterial keratitis","volume":"100","author":"Mannis","year":"2002","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1086\/375244","article-title":"Optical monitoring and treatment of potentially lethal wound infections in vivo","volume":"187","author":"Hamblin","year":"2003","journal-title":"J. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/1\/23\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:05:02Z","timestamp":1760364302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/1\/23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["antibiotics9010023"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9010023","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]}}}